vs
Side-by-side financial comparison of ASHFORD HOSPITALITY TRUST INC (AHT) and Amphastar Pharmaceuticals, Inc. (AMPH). Click either name above to swap in a different company.
ASHFORD HOSPITALITY TRUST INC is the larger business by last-quarter revenue ($259.0M vs $183.1M, roughly 1.4× Amphastar Pharmaceuticals, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs -26.8%, a 40.1% gap on every dollar of revenue. On growth, Amphastar Pharmaceuticals, Inc. posted the faster year-over-year revenue change (-1.8% vs -6.0%). Amphastar Pharmaceuticals, Inc. produced more free cash flow last quarter ($24.6M vs $-86.8M). Over the past eight quarters, Amphastar Pharmaceuticals, Inc.'s revenue compounded faster (3.2% CAGR vs -7.7%).
Ashford Hospitality Trust Inc is a U.S.-headquartered real estate investment trust focused on upper-upscale full-service hotel properties across key U.S. urban, suburban and resort markets. Its portfolio holds assets under top global hospitality brands, serving business and leisure travelers, with a focus on long-term value growth and stable shareholder returns.
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
AHT vs AMPH — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $259.0M | $183.1M |
| Net Profit | $-69.3M | $24.4M |
| Gross Margin | — | 46.8% |
| Operating Margin | -2.6% | 19.4% |
| Net Margin | -26.8% | 13.3% |
| Revenue YoY | -6.0% | -1.8% |
| Net Profit YoY | 44.2% | -35.7% |
| EPS (diluted) | $-12.85 | $0.51 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $259.0M | $183.1M | ||
| Q3 25 | $266.1M | $191.8M | ||
| Q2 25 | $302.0M | $174.4M | ||
| Q1 25 | $277.4M | $170.5M | ||
| Q4 24 | $275.5M | $186.5M | ||
| Q3 24 | $276.6M | $191.2M | ||
| Q2 24 | $316.5M | $182.4M | ||
| Q1 24 | $303.9M | $171.8M |
| Q4 25 | $-69.3M | $24.4M | ||
| Q3 25 | $-60.1M | $17.4M | ||
| Q2 25 | $-30.4M | $31.0M | ||
| Q1 25 | $-20.0M | $25.3M | ||
| Q4 24 | $-124.2M | $38.0M | ||
| Q3 24 | $-57.9M | $40.4M | ||
| Q2 24 | $50.3M | $37.9M | ||
| Q1 24 | $71.6M | $43.2M |
| Q4 25 | — | 46.8% | ||
| Q3 25 | — | 51.4% | ||
| Q2 25 | — | 49.6% | ||
| Q1 25 | — | 50.0% | ||
| Q4 24 | — | 46.5% | ||
| Q3 24 | — | 53.3% | ||
| Q2 24 | — | 52.2% | ||
| Q1 24 | — | 52.4% |
| Q4 25 | -2.6% | 19.4% | ||
| Q3 25 | 4.6% | 13.2% | ||
| Q2 25 | 16.3% | 24.2% | ||
| Q1 25 | 22.2% | 21.9% | ||
| Q4 24 | -17.8% | 24.2% | ||
| Q3 24 | 7.3% | 29.8% | ||
| Q2 24 | 42.8% | 30.3% | ||
| Q1 24 | 50.2% | 27.9% |
| Q4 25 | -26.8% | 13.3% | ||
| Q3 25 | -22.6% | 9.0% | ||
| Q2 25 | -10.1% | 17.8% | ||
| Q1 25 | -7.2% | 14.8% | ||
| Q4 24 | -45.1% | 20.4% | ||
| Q3 24 | -20.9% | 21.1% | ||
| Q2 24 | 15.9% | 20.8% | ||
| Q1 24 | 23.5% | 25.1% |
| Q4 25 | $-12.85 | $0.51 | ||
| Q3 25 | $-11.35 | $0.37 | ||
| Q2 25 | $-6.88 | $0.64 | ||
| Q1 25 | $-4.91 | $0.51 | ||
| Q4 24 | $-13.64 | $0.74 | ||
| Q3 24 | $-12.39 | $0.78 | ||
| Q2 24 | $2.50 | $0.73 | ||
| Q1 24 | $5.99 | $0.81 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $66.1M | $282.8M |
| Total DebtLower is stronger | $2.5B | $608.7M |
| Stockholders' EquityBook value | $-626.4M | $788.8M |
| Total Assets | $2.8B | $1.6B |
| Debt / EquityLower = less leverage | — | 0.77× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $66.1M | $282.8M | ||
| Q3 25 | $81.9M | $276.2M | ||
| Q2 25 | $100.0M | $231.8M | ||
| Q1 25 | $85.8M | $236.9M | ||
| Q4 24 | $112.9M | $221.6M | ||
| Q3 24 | $119.7M | $250.5M | ||
| Q2 24 | $121.8M | $217.8M | ||
| Q1 24 | $111.1M | $289.6M |
| Q4 25 | $2.5B | $608.7M | ||
| Q3 25 | $2.6B | $608.6M | ||
| Q2 25 | $2.6B | $607.7M | ||
| Q1 25 | $2.7B | $603.9M | ||
| Q4 24 | $2.6B | $601.6M | ||
| Q3 24 | $2.7B | $596.4M | ||
| Q2 24 | $2.8B | $586.9M | ||
| Q1 24 | $2.9B | $594.0M |
| Q4 25 | $-626.4M | $788.8M | ||
| Q3 25 | $-548.7M | $776.7M | ||
| Q2 25 | $-485.5M | $757.5M | ||
| Q1 25 | $-446.1M | $751.3M | ||
| Q4 24 | $-419.2M | $732.3M | ||
| Q3 24 | $-288.4M | $727.7M | ||
| Q2 24 | $-225.9M | $713.3M | ||
| Q1 24 | $-276.8M | $672.4M |
| Q4 25 | $2.8B | $1.6B | ||
| Q3 25 | $3.0B | $1.7B | ||
| Q2 25 | $3.1B | $1.6B | ||
| Q1 25 | $3.1B | $1.6B | ||
| Q4 24 | $3.2B | $1.6B | ||
| Q3 24 | $3.3B | $1.5B | ||
| Q2 24 | $3.3B | $1.5B | ||
| Q1 24 | $3.5B | $1.6B |
| Q4 25 | — | 0.77× | ||
| Q3 25 | — | 0.78× | ||
| Q2 25 | — | 0.80× | ||
| Q1 25 | — | 0.80× | ||
| Q4 24 | — | 0.82× | ||
| Q3 24 | — | 0.82× | ||
| Q2 24 | — | 0.82× | ||
| Q1 24 | — | 0.88× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.7M | $32.9M |
| Free Cash FlowOCF − Capex | $-86.8M | $24.6M |
| FCF MarginFCF / Revenue | -33.5% | 13.4% |
| Capex IntensityCapex / Revenue | 27.5% | 4.5% |
| Cash ConversionOCF / Net Profit | — | 1.35× |
| TTM Free Cash FlowTrailing 4 quarters | $-135.5M | $121.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-15.7M | $32.9M | ||
| Q3 25 | $5.5M | $52.6M | ||
| Q2 25 | $16.3M | $35.6M | ||
| Q1 25 | $-25.0M | $35.1M | ||
| Q4 24 | $-23.6M | $29.0M | ||
| Q3 24 | $795.0K | $60.0M | ||
| Q2 24 | $8.0M | $69.1M | ||
| Q1 24 | $-46.5M | $55.3M |
| Q4 25 | $-86.8M | $24.6M | ||
| Q3 25 | $-226.0K | $47.2M | ||
| Q2 25 | $-3.6M | $25.0M | ||
| Q1 25 | $-44.8M | $24.4M | ||
| Q4 24 | $-131.6M | $16.6M | ||
| Q3 24 | $-21.8M | $46.2M | ||
| Q2 24 | $-22.9M | $63.1M | ||
| Q1 24 | $-80.4M | $46.5M |
| Q4 25 | -33.5% | 13.4% | ||
| Q3 25 | -0.1% | 24.6% | ||
| Q2 25 | -1.2% | 14.3% | ||
| Q1 25 | -16.2% | 14.3% | ||
| Q4 24 | -47.8% | 8.9% | ||
| Q3 24 | -7.9% | 24.1% | ||
| Q2 24 | -7.2% | 34.6% | ||
| Q1 24 | -26.5% | 27.1% |
| Q4 25 | 27.5% | 4.5% | ||
| Q3 25 | 2.1% | 2.8% | ||
| Q2 25 | 6.6% | 6.1% | ||
| Q1 25 | 7.2% | 6.3% | ||
| Q4 24 | 39.2% | 6.7% | ||
| Q3 24 | 8.2% | 7.2% | ||
| Q2 24 | 9.8% | 3.3% | ||
| Q1 24 | 11.2% | 5.1% |
| Q4 25 | — | 1.35× | ||
| Q3 25 | — | 3.03× | ||
| Q2 25 | — | 1.15× | ||
| Q1 25 | — | 1.39× | ||
| Q4 24 | — | 0.76× | ||
| Q3 24 | — | 1.48× | ||
| Q2 24 | 0.16× | 1.82× | ||
| Q1 24 | -0.65× | 1.28× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AHT
| Occupancy | $190.2M | 73% |
| Food And Beverage | $51.8M | 20% |
| Hotel Other | $16.6M | 6% |
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
